Cardiac Specific Effects of Thyroid Hormone Analogues

Abstract

There is significant interest in development of thyroid hormone analogues to harness specific properties as therapeutic agents for a variety of clinical indications including obesity, hypercholesterolemia, heart failure, and thyrotoxicosis. To date, most analogues have been designed to target liver specific effects, which can promote weight loss and lipid lowering through either tissue specific uptake or thyroid hormone receptor (TR) β isoform selectivity at the same time minimizing the unwanted cardiac and bone effects. We have developed a molecular biomarker assay to study the induction of the transcription of the cardiac specific α-myosin heavy chain (MHC) gene as a more sensitive and specific measure of thyroid hormone action on cardiac myocytes. We tested 5 TRβ and 1 TRα selective agonists as well as 2 putative TR antagonists in our α-MHC hnRNA assay. Using reverse transcription and polymerase chain reaction, we measured the induction of the α-MHC primary transcript in response to administration of drug. The TRα and only 2 of the TRβ agonists were highly active, when compared to the effect of T₃, at the level of the cardiac myocyte. In addition, our data suggests that the reason that the antagonist NH-3 is not able to block the T₃-mediated induction of α-MHC is that it does not get transported into the cardiac myocyte. Our data suggest that this assay will be useful in preclinical studies of the potential cardiac specific effects of thyroid hormone analogues and that predictions of function based on structure are not necessarily accurate or complete.

Key words

analogue - heart - T₃ - T₄ - triiodothyronine

• References

• 1 Morkin E, Ladenson P, Goldman S, Adamson C. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J Mol Cell Cardiol 2004; 37: 1137-1146
• 2 Brenta G, Danzi S, Klein I. Potential Therapeutic Applications of Thyroid Hormone Analogs. Nat Clin Pract Endocrinol Metab 2007; 3: 632-640
• 3 Ribeiro MO. Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid 2008; 18: 197-203
• 4 Erion MD, Cable EE, Ito BR, Jiang H, Fujitaki JM, Finn PD, Zhang BH, Hou J, Boyer SH, van Poelje PD, Linemeyer DL. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007; 104: 15490-15495
• 5 Castillo M, Freitas BCG, Rosene ML, Drigo RA, Grozovsky R, Maciel RMB, Patti ME, Ribeiro MO, Bianco AC. Impaired Metabolic Effects of a Thyroid Hormone Receptor Beta-Selective Agonist in a Mouse Model of Diet-Induced Obesity. Thyroid 2010; 20: 545-554
• 6 Klein I, Danzi S. Thyroid Disease and the Heart. Circulation 2007; 116: 1725-1735
• 7 Sadow PM, Chassande O, Koo EK, Gauthier K, Samarut J, Xu J, O’Malley BW, Weiss RE. Regulation of expression of thyroid hormone receptor isoforms and coactivators in liver and heart by thyroid hormone. Mol Cell Endocrinol 2003; 203: 65-75
• 8 Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Treatment of Dyslipidemia with the Thyroid Hormone Analog Eprotirome in Statin-Treated Patients. New Engl J Med 2010; 362: 906-916
• 9 Everts ME, Verhoeven FA, Bezstarosti K, Moerings E, Hennemann G, Visser TJ, Lamers JMJ. Uptake of Thyroid Hormones in Neonatal Rat Cardiac Myocytes. Endocrinology 1996; 137: 4235-4242
• 10 Danzi S, Ojamaa K, Klein I. Triiodothyronine-Mediated Myosin Heavy Chain Gene Transcription in the Heart. Am J Physiol Heart Circ Physiol 2003; 284: H2255-H2262
• 11 Balkman C, Ojamaa K, Klein I. Time course of the effects of thyroid hormone on cardiac gene expression. Endocrinology 1992; 130: 2001-2006
• 12 Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC, Scanlan TS. A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 1998; 5: 299-306
• 13 Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000; 141: 3057-3064
• 14 Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen NH, Baxter JD, Scanlan TS. Effects of the thyroid hormone receptor GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3’-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661
• 15 Baxter JD, Webb P, Grover G, Scanlan TS. Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight. Trends Endocrinol Metab 2004; 15: 154-157
• 16 Johansson L, Rudling M, Scanlan TS, Lundasen T, Webb P, Baxter J, Angelin B, Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005; 102: 10297-10302
• 17 Baxter JD, Dillmann WH, West BL, Huber R, Furlow JD, Fletterick RJ, Webb P, Apriletti JW, Scanlan TS. Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 2001; 76: 31-42
• 18 Lim W, Nguyen NH, Yang HY, Scanlan TS, Furlow JD. A thyroid hormone antagonist that inhibits thyroid hormone action in vivo. J Biol Chem 2002; 277: 35664-35670
• 19 Nguyen NH, Apriletti JW, Cunha Lima ST, Webb P, Baxter JD, Scanlan TS. Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. J Med Chem 2002; 45: 3310-3320
• 20 Grover GJ, Dunn C, Nguyen NH, Boulet J, Dong G, Domogauer J, Barbounis P, Scanlan TS. Pharmacological profile of the thyroid hormone receptor antagonist NH3 in rats. J Pharmacol Exp Ther 2007; 322: 385-390
• 21 Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, Webb P, Scanlan TS, Nilsson S. Structure-Based Design and Synthesis of a Thyroid Hormone Receptor (TR) Antagonist. Endocrinology 2002; 143: 517-524
• 22 Schapira M, Raaka BM, Samuels HH, Abagyan R. Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci USA 2000; 97: 1008-1013
• 23 Borngraeber S, Budny MJ, Chiellini G, Cunha-Lima ST, Togashi M, Webb P, Baxter JD, Scanlan TS, Fletterick RJ. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 2003; 100: 15358-15363